[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cancer-stage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cancer-stage":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":39,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100545979","pancreatic-cancer-detection-consortium-100545979",false,"NCT06388967","Pancreatic Cancer Detection Consortium","Early Detection of Pancreatic Cancer: Prospective Study","PCDC","Inclusion Criteria:\n\n* Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)\n* Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.\n* Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)\n\nExclusion Criteria:\n\n* Lack of written informed consent.",true,"ALL","18 Years",{"count":21,"type":22},2000,"ESTIMATED","OBSERVATIONAL","This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.",[26,27,28,29,30,31,32,33,34,35,36,37,38],"Pancreatic Cancer","Pancreatic Carcinoma","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Neoplasms","Pancreatic Cancer Stage I","Pancreatic Cancer Stage","Pancreatic Cancer Resectable","Pancreatic Cancer Stage 0","Pancreatic Cancer Stage II","Pancreatic Cancer Stage III","Pancreatic Cancer, Adult","Pancreatic Cancer Non-resectable",[40,41,42,43,44],"Micro RNA","Exosome","Cell free","Early detection","Screening","RECRUITING","2025-12-17",{"date":48,"type":49},"2025-12-19","ACTUAL",{"date":51,"type":49},"2023-03-15",{"date":53,"type":22},"2026-06-18",{"name":55,"class":56},"City of Hope Medical Center","OTHER",11,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100565792","early-phase-1-phase-iit-trial-of-sna014-100565792","NCT06646783","Phase IIT Trial of SNA014","Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET\u002FCT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer","Inclusion Criteria:\n\n* Age range of 18 to 75 years old (including boundary values);\n* Individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (ICF);\n* Diagnosed G\u002FGEJ adenocarcinoma and pancreatic cancer;\n* Gastroscopy\u002FCT\u002FMRI\u002FPET-CT examination results within the past month (if any);\n* Pathological test results and Claudin18.2 immunohistochemistry results within the past year (if available).\n\nExclusion Criteria:\n\n* Merge patients with other clearly diagnosed malignant tumors:\n* Uncontrolled severe infections or individuals with other serious illnesses;\n* Those with an expected survival period of less than or equal to three months;\n* Pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial;\n* investigators determine that patients who are not suitable to participate in this study;","75 Years",{"count":67,"type":22},28,"INTERVENTIONAL",[70],"EARLY_PHASE1","68Ga labeled Claudin 18.2 contrast agent combined with PET\u002FCT for gastric or gastroesophageal junction",[73,74,32],"Adenocarcinoma of the Stomach","Adenocarcinoma of GE Junction","NOT_YET_RECRUITING","2024-10-15",{"date":78,"type":49},"2024-10-17",{"date":80,"type":22},"2024-10-20",{"date":82,"type":22},"2025-11-20",{"name":84,"class":85},"SmartNuclide Biopharma","INDUSTRY",1]